Appeals court sides with FDA in lawsuit over fat-derived stem cell procedure
The FDA’s crack down on stem cell clinics hawking unapproved products for conditions with limited options is off and running, with a new court win for the agency at the 11th Circuit of Appeals on Wednesday.
The court found that Florida-based US Stem Cell’s biological material implanted into the patient “is not the same as that removed,” and the procedure “intends the stem cells to perform functions after the procedure beyond the basic functions the stem cells performed prior to the procedure.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.